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ABSTRACT 
 
THE EFFECT OF CAFFEINE AND CHOLINE ON SHORT-TERM MEMORY 
 
 
 
By 
Natasha Nagrecha 
May 2012 
 
Thesis supervised by Dr. David Johnson 
 This study sought to determine whether caffeine combined with choline 
could improve short-term memory in healthy adults. The study tested the effect of choline 
(2 gm) alone and in combination with several concentrations of caffeine (25 mg, 50mg 
and 100mg) on short-term verbal and visual memory and attention. The Wide Range 
Assessment of Memory and Learning-2 was utilized. Choline 2 gm + caffeine 25 mg 
group showed significantly (p<0.05) higher overall memory performance whereas 
memory performance in the choline 2 gm + caffeine 50 mg group was significantly 
impaired compared to placebo. The data suggest that specific combinations of caffeine 
and choline can either facilitate or impair short-term memory in adults with normal 
cognitive function.  Future studies of caffeine and choline combinations will test memory 
performance in subjects with memory impairment. 
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1.0    Introduction   
1.1                  Goal of the study  
                       Memory loss, such as misplacing keys or forgetting something when 
grocery shopping, is a natural part of life that occurs in most individuals at almost any 
age. There are different types of memory loss such as short-term, long-term, temporary or 
permanent memory loss (1). There are various causes of memory loss such as vitamin 
deficiencies, alcoholism, head injury in addition to various disease states such as 
Parkinson’s disease, Alzheimer’s disease, depression and vascular dementia (2).   
 Symptoms of memory loss typically appear in older adults, but it is not 
uncommon to also see them in younger adults. General approaches to prevent memory 
loss include exercising, reading, remaining social and maintaining a healthy diet (3,4). 
Certain dietary substances such as coffee, tea, eggs, soya etc. have been studied for their 
beneficial effect on memory (5,6). This study seeks to determine whether a combination 
of two dietary supplements can improve short-term memory in healthy adults with the 
hope of developing a drug therapy to treat memory impairments.   
 Caffeine, a common ingredient of a number of memory supplements, energy 
drinks and food items such as coffee has been associated with enhanced cognitive 
performance. Caffeine has been shown to be effective in improving short-term memory 
in several studies (7-13).  Choline, a dietary component of dairy products, has also been 
demonstrated to improve memory performance (14,15).  The rational for testing the 
combination of caffeine and choline is that choline is the synthetic precursor for the 
neurotransmitter Ach, which is important for memory function (16).  Caffeine has been 
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shown to increase Ach release in the hippocampus, an area of the brain involved with 
memory processing (17).  Therefore, the combination of the two drugs may be synergistic 
or additive for enhancing memory and other cognitive functions. The cholinergic system 
is important since damage or dysfunction of the cholinergic neuronal tracts are associated 
with a number of conditions associated with memory loss and dementias such as 
Alzheimer’s disease (18,19). 
 The purpose of the proposed research is to test the effect of the combination of 
choline and caffeine on short-term memory in normal healthy volunteers and determine 
whether there is an optimal combination of the two drugs for enhancing memory. We 
tested the effect of choline alone, three dose combinations of caffeine and choline and 
placebo on visual and auditory short-term memory. If a particular combination of 
caffeine and choline shows beneficial effects on memory function in healthy volunteers, 
it may have potential benefits for patients with cognitive impairments or dementias. The 
results of this clinical investigation will provide pilot data to support the hypothesis that 
the combination of caffeine and choline is beneficial in improving memory and may be 
used as a therapy in patients with memory loss.  
 
1.2                   Background and Significance  
1.2.1                Memory  
1.2.1.1  Defining Memory 
  Memory is the ability of an organism to store, retain and subsequently 
recall information (20).  Without memory, survival would be difficult, since it would be 
necessary to gather information all the time without being able to store it.  
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Memories have been classified broadly as sensory, short-term or long-term memory 
based on the duration of time for which it can be stored. Short-term memory can be 
stored from a few seconds to a few minutes whereas as long-term memory can be stored 
for an unlimited period. Memories are formed through complex biochemical sequences; 
however, the exact mechanism has yet to be elucidated. Memory formation has been 
associated with different neuronal signaling pathways in the brain. Increases in 
neurotransmitters, such as dopamine and acetylcholine, have been linked to formation of 
memories. One of major pathologies underlying conditions associated with memory loss 
has been the loss of neurons such as cholinergic and dopaminergic neurons.  Some 
conditions associated with memory loss include multi-infarct dementia, Alzheimer’s 
disease, and Parkinson’s disease.  
 
1.2.1.2 Classification of Memory 
Due to its complex nature, memory is classified by various factors that are 
characteristic of it. A basic and general classification of memory can be made based on 
retention time, information type and temporal direction. (20).  Based on retention time, 
memory is broadly classified into sensory memory, short-term memory, and long-term 
memory.  Short-term memory, as it name implies, stores memory for a few milliseconds 
to seconds with limited capacity. Sensory memory corresponds to the initial moment of 
perception while long-term memory is more stable, can store information for a lifetime 
and, thus, has substantially greater capacity than short-term memory.  
    Based on information types, long-memory is classified into procedural 
memory and declarative memory.  Procedural memory or “implicit memory” involves 
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learning motor skills that improves with repetition and unconsciously accesses 
information from past experiences. Examples of procedural memory include speaking or 
swimming. Declarative memory or “explicit memory” requires a conscious recollection 
of events. Declarative memory is further classified into semantic memory, episodic 
memory and autobiographical memory.  Semantic memory encodes abstract knowledge 
of the world.  A good example of this is the statement “Paris is the capital of France.”.  
Episodic memory is memory that deals with information related to a particular event in 
the past, including time and place, for example, remembering an episode from a 
television show. Autobiographical memory is a form of memory that involves 
remembering information from one’s past such as remembering a vacation. Based on 
temporal direction, memory is also classified into retrospective memory and prospective 
memory.  Retrospective memory recalls events that occurred in the past while 
prospective memory is recall of events to occur in the future, for example, remembering 
to attend a meeting.  This time of memory is also called “remembering to remember”.  
 
1.2.2                Memory Processes  
Memory formation is a complex process broadly made up of four different 
stages. The first stage is acquisition of information from the environment. The second 
step is memory consolidation or information processing. This is followed by memory 
storage and the final stage is memory retrieval (Figure 1; 21). The Sensory Store is the 
part of memory that holds unanalyzed sensory information for a fraction of a second.  
This provides the brain an opportunity for additional analyses to occur following the 
physical termination of a stimulus. The filter is an aspect of attention in which certain 
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perceptional information is lost and not recognized while other information is recognized 
and receives attention. Pattern recognition is the stage of perception when a stimulus is 
recognized. The perceived stimuli are consolidated and stored as short-term and/or long-
term memories. 
Figure 1: Processes involved in memory formation 
 
1.2.3  Memory Tasks  
Memory tasks are activities done to measure memory. Different memory 
tasks or activities measure different types of memories for example long-term vs short 
term memory or different components of memory such as visual memory or verbal 
memory. The three major types of memory tasks include paired associate learning, free 
recall and recognition. Paired associate learning is learning that associates an event, 
person, object or word with another stimulus (e.g., associating the color blue with the 
sky). Free recall is recollection of unassociated events like remembering a list of words. 
Recognition is recollection by recognition of an event or a place.  This can be equated to 
remembering a place from a picture. 
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1.2.4                Short-term Memory  
In theory, short-term memory is a system of limited capacity, which 
maintains and holds information. This information assists in formation of thoughts in 
humans by acting as an interface between perception, long term memory and action (22). 
According to the Baddeley and Hitch model, the storage of a limited amount of verbal or 
visual memory occurs through specific areas in the brain. These areas combine to form 
the phonological loop and the visuospatial sketchpad (23), which correspond to the verbal 
and visual memory areas of the brain. The capacity to perform the more complex 
activities that include memory processing are ascribed to the central executive (24), 
which is responsible for storage and retrieval of information and directing the flow of 
information through short-term memory.  
 
Figure 2: Representation of the Baddeley model (24) 
 
1.2.4.1            Neuroanatomy of Short-term memory  
Short-term memory is composed of an auditory component and a visual 
component. The figure below is a representation of brain areas involved in the formation 
of short-term memory through the visual and auditory components. These areas include 
prefrontal cortex, hippocampus, amygdala, basal forebrain and thalamus. Table 1 shows 
that the different aspects of memory are located all throughout the brain that deal with 
verbal short-term memory, visual short-term memory and attention/concentration.  
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Figure 3: Sagittal view of the adult brain, with Brodmann areas marked (25) 
 
 
Type of Short-term 
memory 
Cortical Areas  Hemisphere Brodmann 
areas 
Phonological 
Storage 
Rehersal  
Posterior paretial 
Broca’s area, premotor 
cortex, 
Supplementary motor 
cortex 
 
Left 
Left  
 
Left 
 
40  
44,6 
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Spatial 
Storage  
Rehersal 
Inferior prefrontal  
Anterior occipital, 
posterior parietal 
Premotor cortex 
Right 
Right 
Right 
47 
19,40 
6 
Working 
memory/executive 
processes 
Dorsolateral prefrontal 
cortex 
Left/bilateral 9,10,44,45,46 
 Table 1: Areas of the brain associated with Short-term memory (25) 
 
1.2.5               Attention and Memory  
The amount of memory formation is dependent on the 
attention/concentration span of a person. Attention is component of cognizance that is 
under human control. It is of limited capacity and resources and thus it acts as the filter 
for the information that we take in through our surroundings. (26).  Attention governs the 
extent of information processing and can influence the amount of information stored. 
Loss of attention prevents the formation of conscious memories. Brain areas important 
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for memory, such as the hippocampus and medial temporal lobe, are also utilized in 
attention tasks (27).  Although independent from memory, attention directly controls 
memory process at all levels. Both caffeine and choline have been shown to influence 
attention (28,29). In this study, attention/concentration was also measured as a 
component of memory.  
 
1.2.6                Memory and Cholinergic System  
The cell bodies of cholinergic neurons are densely present in the basal 
forebrain, the axons of which extend into the thalamus, prefrontal cortex, hippocampus 
and amygdala. Literature suggests the importance of the cholinergic system in memory 
formation. Anticholinesterases are the first line of treatment for conditions such as 
Alzheimer’s disease. Also, there is loss of cholinergic neurons in the basal for brain in 
certain conditions of dementia. Finally, scopolamine, which is a muscarinic antagonist is 
widely known to cause amnesia. Anatomically, the cholinergic system is composed of the 
basal forebrain, cerebral cortex, brain stem, thalamus and basal ganglia. The basal 
forebrain extends cholinergic projections to the cerebral cortex, hippocampus, 
hypothalamus and amygdala. Memories are formed by neurotransmitter release at the 
synapse. 
The cholinergic system has been related to the formation of memory in 
several studies. Newhouse et.al, 2001 showed that the cholinergic system is involved in 
several areas of thought such as attention and working memory. It is also shown to 
improve performance in effortful tasks (30).  According to the cholinergic hypothesis of 
geriatric memory dysfunction, healthy older adults and demented patients show an 
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imbalance in the cholinergic system. The restitution of cholinergic function may reverse 
conditions of cognitive loss (18).  
Several studies investigated the relation between cholinergic loss and 
memory dysfunction. Whitehouse et al., (1982) showed a reduction in the number of 
cholinergic neurons in the forbrains of patients with Alzheimer’s disease and dementia 
(31). Bartus et al., (1982) showed a reduction in the activity of choline acetyl transferase 
associated with geriatric memory dysfunction (18). Bierer et al., (1995), in an 
Alzheimer’s disease patient population, demonstrated a reduction in cholinergic markers 
(32). Finally,  
Sunderland et al., (1985) showed that nicotinic and muscarinic receptor antagonists 
produced age- and disease-related deficits in memory resembling aging and AD (33).  
Acetylcholine is the neurotransmitter of the cholinergic system and the loss of 
acetylcholine has been related to memory disorders such as Alzheimer’s disease. There 
are two types of acetylcholine receptors that are known, nicotinic and muscarinic. In the 
brain, evidence suggests a role for muscarinic receptors in memory function (34).         
There are five types of muscarinic receptors: M1, M2, M3, M4 and M5. Their 
distribution in the brain is in Table 2. 
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Figure 4: Acetylcholine synthesis and release 
 
Receptor 
Sub-types 
Regional Abundance Cellular Localization Synaptic Localization 
M1 
Abundant in forebrain 
(neocortex, hippocampus 
neostriatum) 
Pyramidal neurons Striatal 
spiny neurons 
Post >> Presynaptic 
M2 
Moderately abundant 
throughout brain 
Cholinergic neurons, 
nonpyramidal neurons in 
cortex and hippocampus 
Pre >> Postsynaptic 
M3 
Low levels throughout 
brain 
Neuronal Unknown 
M4 
Abundant in neostriatum, 
moderate levels in 
hippocampus and cortex 
Striatal spiny neurons 
Associational and 
commissural 
hippocampal 
projections 
Pre and Postsynaptic 
M5 
Low levels in hippocampus, 
substantia nigra 
Pyramidal neurons, 
substantia nigra pars 
compacta, microglia 
Unknown 
Table 2: Distribution of Muscarinic Receptors 
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  Fig. 4 shows the biochemical process of Ach formation and release. 
Choline, in the presence of choline acetyltransferase combines with acetyl coenzyme A to 
form Ach. This Ach is then stored in the vesicles in the presynaptic cholinergic neuron. 
The transport into the vesicles occurs through VAT or vesicular transporters. On 
depolarization, the vesicles fuse with the presynaptic membrane and release the Ach into 
the synapse. This released Ach then attaches to the various presynaptic and postsynaptic 
muscarinic and nicotinic receptors, which leads to a host of signaling mechanisms that 
lead to formation of memories.  
  Acetylcholine may enhance memory encoding via muscarinic presynaptic 
inhibition of excitatory feedback synapses within cortical circuits (35; Figure 4). 
Modeling shows that the reduction of excitatory feedback enhances encoding by reducing 
interference from previous retrieval (35).  There is evidence suggesting a role for M1 
acetylcholine receptors in memory formation (36,37) and that M2 receptors are involved 
in memory formation and consolidation (38). In addition, there is also evidence 
supporting the importance of M3, M4 and M5 cholinergic receptors in memory 
formation, consolidation and learning. (39,40,41).  The mechanism by which cholinergic 
neurotransmission is involved in memory and learning is still being ascertained; however, 
a definite role of muscarinic cholinergic receptors in cognition has been established.  
 
1.2.6.1 Pharmacokinetic and Pharmacodynamics of Choline  
Choline is required for the structural integrity and signaling functions of 
cell membranes, methyl group metabolism, and neurotransmitter synthesis (15). Under 
certain conditions, increasing the availability of choline can enhance cholinergic 
neurotransmission.  Moreover, when cholinergic neurons are physiologically active, the 
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rate of synthesis and release of acetylcholine varies directly with the availability of free 
choline (42). Choline is not only the precursor of Ach, it is also the precursor of 
phosphotidylcholine and sphingomyelin.  These phospholipids serve as structural 
constituents of all cell membranes and act as sources for the synthesis of trimethylglycine 
and trimethylamine, second messengers used in receptor-mediated interneuron signaling 
(43).  Thus, if the availability of choline is decreased, cholinergic neurons may not be 
able to function normally. Recent studies suggest that dietary choline can prevent 
memory impairment in vivo (44,45).  
 
1.2.6.2             Plasma Choline Concentration  
Dieary intake of choline can raise plasma choline concentrations upto 
82%. This surge can remain elevated for upto one hour. This increase in plasma levels 
causes   choline to cross the blood brain barrier (46). The rate limiting step for this 
process is the high affinity choline transporters.  
 
1.2.6.3 Choline Metabolism 
Free choline concentration in the serum and tissues is dependent on the 
dietary intake of choline. One hour following a single oral dose of choline, the quantity of 
choline in the CSF is elevated. In the brain, choline is converted to acetylcholine by 
choline acetyltransferase. Membrane depolarization causes the release of acetylcholine 
into the synaptic cleft. After release, acetylcholine is hydrolyzed to acetate and choline by 
acetylcholineesterase (Figure 5).  
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Figure 5: Acetylcholine synthesis and metabolism. Choline, in the presence of choline acetyltransferase, 
combines with acetyl-CoA to give Ach. Acetylcholine esterase breaks Ach to release choline and acetate. 
 
1.2.7                Memory and Caffeine  
1.2.7.1             Caffeine effects in the human body  
Caffeine is a xanthine alkaloid found in beverages including tea, coffee 
and soda. Caffeine is regularly consumed by millions of people around the world. Owing 
to caffeine content, coffee is the best-known psycho-stimulant that improves cognitive 
function (47).   
Caffeine has ergogenic (enhances physical performance), psycho-
stimulant, nootropic (enhances cognition, learning and memory) and diuretic properties. 
It affects various systems of the body differently at different doses. Caffeine is known to 
have a number of effects on behavior, memory, mood and attention in humans. Caffeine 
is also known to have a diuretic effect and alters the heart rate and blood pressure if 
consumed regularly (59). Overconsumption of caffeine may affect other organ systems. 
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For example, caffeine has been shown to affect the digestive system by acting as a 
laxative and, in some individuals, caffeine consumption may cause increases in stomach 
acidity leading to heartburn. In others, caffeine may increase muscle contraction, increase 
pain and may act as a respiratory stimulant by increasing ventilation.  
              
1.2.7.2            Caffeine Metabolism  
Following ingestion, caffeine is rapidly absorbed from the gastrointestinal 
tract and reaches approximately 99% absorption within 45 minutes (52-57). Caffeine is 
metabolized in the liver to form dimethyl- and monomethylxanthines, dimethyl- and 
monomethyl uric acids, trimethyl- and dimethylallantoin and uracil derivatives (58). 
Demethylation via C08 oxidation and uracil formation occurs mostly within the liver 
microsome.  
 
1.2.7.3            Animal and Human studies 
             Caffeine’s beneficial effects have been studied extensively in animals and 
humans (76,77). Improved performance in psychological tasks has been reported 
following caffeine intake in normal subjects, even with doses as low as 32 mg. Observed 
effects included enhanced vigilance, arousal, alertness, psychomotor speed, and mood.  
Improved learning and memory by caffeine has been demonstrated in a study by Riedel et 
al., 1995 (12). Chronic consumption of caffeine has been shown to prevent symptoms of 
memory loss in some animal models of memory decline, using the Morris water-maze 
test (94). Because of caffeine’s performance-enhancing and memory-enhancing effects, it 
is classified as both an ergogenic and nootropic molecule, respectively.  These properties 
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of caffeine are thought to be due to the structural similarity of caffeine to adenosine 
(100). 
 
1.2.8                Adenosine receptors and Caffeine  
  As stated previously, caffeine is structurally similar to adenosine (Fig. 
6A).  As such, caffeine exerts its actions through adenosine receptors and signal 
transduction cascades associated with adenosine receptor signaling (Fig. 6B). Four 
subtypes of adenosine receptors have been identified: A1, A2A, A2B and A3 (63).  Of these, 
receptor A3 is not affected greatly by caffeine or other methylxanthines, and receptor A2B 
requires very high concentrations of adenosine for activation. Hence, these are unlikely to 
be involved in the behavioral effects of caffeine. However, receptors A1 and A2A are 
activated by low concentrations of adenosine and are therefore, most likely the targets for 
caffeine effects. Both A1 and A2A are G-protein coupled receptors, with A1 receptors 
linked to Gi proteins causing inactivation of adenylyl cyclase and A2A receptors linked to 
Gs proteins causing adenylyl cyclase activation. Thus, the two receptors have opposing 
actions.  
 Caffeine affects neurotransmitter release and neuronal firing through antagonism 
of adenosine A1 receptors. Caffeine, at concentrations that equate to normal physiological 
doses (i.e., 0-4 mg/kg) binds to both A1 and A2A receptors with similar affinity (48) and 
acts as an adenosine receptor antagonist at A1 and A2A adenosine receptors (60) . By 
binding to A1 and A2A adenosine receptors, caffeine is thought to increase the release of 
acetylcholine in the brain. Even though caffeine binds to A2A adenosine receptors, 
evidence in the literature suggests that its nootropic effect is mainly through interaction 
with A1 receptors. At higher doses (i.e., millimolar range), caffeine acts as a calcium 
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reuptake inhibitor (49); inhibition of calcium reuptake within the neuron leads to the 
mobilization of intracellular calcium within the neuron itself, increasing its activity. At 
these same doses, caffeine inhibits phosphodiesterases within the neuron (50, 51) leading 
to increases in cAMP by preventing the enzymatic degradation of cAMP.  
 
 
 
Fig. 6a. Structural comparison between Caffeine and Adenosine (100) and Fig. 6b. 
Caffeine’s Proposed Mechanism of Action: Fig. 6b, shows the mechanism of action of 
caffeine at different doses. Caffeine, at dietary doses, acts as a competitive antagonist at 
the adenosine receptors. In millimolar concentrations, caffeine acts as a calcium reuptake 
inhibitor and a phosphodiesterase inhibitor.  
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  The mechanism of action for the stimulant effects of caffeine in humans 
usually occurs between the effective dose (10-250mg) and toxic dose (>400mg); 
however, this dose may vary between individuals. When attempting to ascribe which 
mechanism underlies caffeine’s effects on memory, the data suggest that it is through its 
actions at adenosine receptors.  In support of this, caffeine’s actions on the release of 
intracellular calcium (49) and on its ability to inhibit cyclic nucleotide phosphodiesterase 
occurs at higher concentrations (mM concentrations) than what is found in a human diet 
(50) thus ruling out caffeine’s effects on memory through this mechanism. The same 
holds true for caffeine’s effects on 5’-nucleotide phosphatase and alkaline phosphatase, 
which also occurs at only millimolar concentrations (62).  Both in vivo and in vitro 
studies confirm that endogenous adenosine has an inhibitory effect on acetylcholine 
release via A1 adenosine receptors (71) and that caffeine facilitates the release of 
acetylcholine from the brain (68-70). Thus, caffeine is hypothesized to affect memory 
processes by acting as an A1 adenosine receptor antagonist increasing Ach release 
through rises in intracellular cAMP levels within the neuron. 
  It is known that caffeine increases turnover of several monoamine 
neurotransmitters, including 5-hydroxytryptamine (5-HT), dopamine and noradrenaline 
(64). It has also been shown that cholinergic neurons are tonically inhibited by adenosine 
and that caffeine consequently increases their firing rate (101).  Because both dopamine 
and noradrenaline neurons are involved in arousal, there is ample evidence to suggest that 
the central stimulatory effect of caffeine could be through the inhibition of A1 receptors. 
In addition, it has been shown that adenosine A1 receptors influence the binding of D1 
dopamine receptor agonists (65-67).  
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1.2.9  Synergism of Caffeine and Choline  
             Cholinergic antagonism in the hippocampus induces dose-dependent and 
delay-dependent deficits characteristic of impaired short-term memory retention (72). 
The basal forebrain cholinergic projection system is involved in cognitive processes, and 
dysfunction in the septohippocampal or basal-cortical pathways system has been linked 
to learning and memory impairments (73,74,75). Caffeine enhances the release of Ach 
whereas choline increases the production of Ach. Thus, we expect to see a synergistic 
effect of the two drugs on short-term memory of healthy adult humans. 
 
1.3  Hypothesis and Specific Aims 
Hypothesis:  
The combination of caffeine and choline will improve short-term memory in human 
adults with normal cognitive function.  
Specific aim:  
To investigate the effect of choline alone and in various combinations with caffeine on 
short-term memory in healthy adult and middle aged human subjects.  
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2.0               Clinical Trial 
2.1                   Testing Cohort  
2.1.1                Human Subjects  
The study consisted of 125 human volunteers between 30 to 65 years of 
age. The Institutional Review Board approved recruitment of human subjects for this 
trial. The sample size was determined by doing a power analysis after collecting 
preliminary data.  
2.1.2                Exclusion and Inclusion Criteria  
  Due to possible effects on memory, subjects taking any of the following 
medications were excluded from the study:  alcohol, antihistamines with sedating side 
effects, sedative-hypnotics, stimulants, and illegal drugs.  Subjects were also excluded if 
they had an average caffeine intake of less than 50 mg/day (equivalent to less than half 
cup of coffee), or more than 300 mg/day day (more than three cups of coffee a day). The 
reason for this restriction was that if the subjects normally ingest less than 50 mg 
caffeine, they might be overly sensitive to the effects of caffeine. Conversely, if a subject 
normally ingests more than 300 mg of caffeine daily, the effects of the doses of caffeine 
may be diminished as a consequence of tolerance (76,77). Since caffeine can affect 
cardiovascular function (78,79), subjects were excluded from the study if they had any of 
the following conditions: uncontrolled blood pressure (>140/90 or elevated and currently 
not taking any blood pressure medication), history of heart failure; cardiac arrhythmias, 
previous heart attack, history of seizures, and pregnant or breast feeding.  Because 
caffeine and choline are eliminated from the body through the kidneys, subjects with 
kidney disease were also excluded from the study. Lastly, any subject who was taking a 
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memory-enhancing medication such as gingko biloba, Aricept, Namenda, Exelon, or 
Razadyne were also excluded from the study. 
 
2.2                   Materials 
2.2.1                Drugs  
Capsules of the same size, number and color were given to each subject. 
The capsules contained one of the following drug combinations. a) Choline 2 gm, b) 
Choline 2 gm + Caffeine 25 mg, c) Choline 2 gm + Caffeine 50 mg, d) Choline 2 gm + 
Caffeine 100 mg , e) Placebo. Pleasant Hills Apothecary provided the drugs.  Choline 
was administered as choline bitartarate and placebo was magnesium stearate.  
 
2.2.2                Testers  
The testers who administered the drugs and memory instrument were 
graduate students from the School of Education and Graduate School of Pharmaceutical 
sciences at Duquesne University. Testers were trained at the School of Pharmacy, 
Duquesne University to conduct this testing using guidelines established in the Wide 
Range Assessment of Memory and Learning 2 kit (PAR, Lutz, Florida)  Blood pressure 
measurements were taken using the Omron HEM-711 DLX automatic blood pressure 
monitor.   
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2.3  Methodology and Procedure  
2.3.1 Subject Recruitment and Screening  
  Subjects were recruited from the city of Pittsburgh through advertisements 
on the Duquesne University campus, and the websites Craigslist and Centre for 
Behavioral and Decision Research (CBDR). (Appendix A). The age of the subjects was 
between 30 and 65 years. Potential subjects were screened several weeks before the 
actual day of testing. The initial screening was done over the phone or through email to 
ensure that the participant was eligible for the study based on the exclusion criteria. If 
eligible, the subjects were asked to join the study and then given an appointment to come 
to Duquesne University for testing.  
 
2.3.2 Consent 
 Subjects were briefed on the details of the project using non-scientific 
terminology. Subjects had the entire procedure explained to them both verbally and in 
writing and were given an informed consent form that explained the procedure and 
selection criteria in detail. Subjects were informed about the effects and side effects of 
caffeine and choline. All participants signed a voluntary consent form to participate in the 
study. Subjects had the right to end participation in the study at any time. (Appendix A)  
 
2.3.3 Preparation and Procedure of Trial 
 One hundred twenty five male and female subjects between 30 and 65 
years of age were recruited for the study. Testing was performed on the Duquesne 
University campus. Each subject visited the testing center once for the testing session.  
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The subjects were asked to refrain from consuming any medication, food or drink 
containing caffeine for at least eight hours prior to their scheduled appointment. On the 
day of testing, subjects were given a unique identifier number to protect their privacy. 
Before testing, the procedure was explained and the subjects completed the consent form.  
Subjects were divided into five treatment groups with 25 subjects per group. Subjects 
received one of four dose combinations or placebo as shown below. The capsules were 
formulated in such a way as to make it impossible to tell the difference in content by 
taste, color, or odor. The testing sessions were randomized so that during the test neither 
the subject nor the tester knew which treatment capsules were administered. 
           
 
 
 
 
 
Table 3.  Drug and dose combinations used for study 
 
  Forty minutes after administration of the capsules, the memory tests were 
administered. To determine the effects of treatments on blood pressure, blood pressure 
was checked prior to and thirty minutes following capsule administration.  
 
2.3.4  Testing Battery: WRAML2  
The study was conducted using standardized tests from the Wide Range 
Assessment of Memory and Learning Second Edition. The WRMAL 2 is a standardized 
      GROUPS CAFFEINE          CHOLINE 
      I         - 2gm. 
     II    25mg.  2gm. 
     III   50mg.  2gm. 
                   IV   100mg.  2gm. 
     V                  Magnesium Stearate 
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and validated psychometric instrument commonly used for measuring performance in 
humans. The WRAML 2 provides an integrated set of memory tests that can be used 
across a life span. Six tests were administered: Verbal Learning, Design Memory, Picture 
Memory, Story Memory, Finger Windows and Number/Letter tests. Using the WRAML 
2 administration and scoring manual, raw scores from these tests were combined to give 
three indices: Verbal Memory Index, Visual Memory Index and the Attention/ 
Concentration Index. The indices are scores that have been standardized, accounting for 
the age of the subject. This allows for direct comparisons of scores between subjects of 
different ages. The three indices were measures of the auditory, visual and the 
attention/concentration components of memory, respectively. These indices were 
combined to form a General Memory Index, which is a reflection of the overall short-
term memory performance of the subject. A Screening Memory Index, which excludes 
the attention/concentration scores, was also calculated. Based on a nationwide validation 
of the test, each of the indices has a mean of 100 and standard deviation of 15.  
The WRAML 2 Administration and Technical manual provides 
information about the validity and reliability of the WRAML 2 tests. The WRAML 2 has 
the following correlations with other measures of memory: Wechsler Memory Scale 
(WMS-III)-0.60, Children’s Memory Scale (CMS)-0.49, Test of Memory and Learning 
(TOMAL)-0.69. The relation between California Verbal Learning Test (CVLT) and 
CVLT-II with the Verbal Memory Index were 0.64 and 0.68. These are high to 
moderately high values of correlation and provide evidence of convergent validity. 
Person separation   reliability (ability of test to distinguish between persons on the basis 
of total items answered correctly) for the six core tests ranges from .85-0.94.And, Item 
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separation reliability (indicates how well items define the variable being measured) 
ranges from 0.99-1.00. Reliability coefficients for the three indices are listed in the 
sections below.  
 
2.3.5 Verbal Memory Tests 
                        To assess verbal memory, two tests were administered to the study 
subjects that included a Story Memory Test and a Verbal Learning Test.  For the Story 
Memory Test, a short story was read to the subjects. After the reader finished, the tester 
asked the subject to recollect as much of the story as possible. This test had a maximum 
score of 117 points. For the Verbal Learning Test, a list of words was first read to the 
subjects and then the subjects were asked to repeat as many words from the list as 
possible.  This test had a maximum score of 64 points. Raw scores from the Story 
Memory Test and Verbal Learning Test were scaled, combined, and converted to the 
Verbal Memory Index using the WRAML 2 Software. The Verbal Memory Index has a 
Reliability Coefficient of 0.92, which means that there is 92% confidence that the tests 
are measuring verbal short-term memory.  
 
2.3.6 Visual Memory Tests 
To assess visual memory, two tests were administered, a Picture Memory 
Test and a Design Memory Test.  For the Picture Memory Test, subjects were asked to 
look at a picture carefully for ten seconds. They were then shown another picture that 
looked similar, but with a few changes. The subjects were asked to identify the 
differences between the two pictures. This test had a maximum score of 51 points. For 
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the Design Memory Test, subjects were shown five design cards, each being shown for 
10 seconds. The cards were then withdrawn and the subject was asked to redraw the 
designs on the response forms. This test had a maximum score of 60 points. Raw scores 
from the Picture Memory Test and Design Memory Test were scaled, combined, and 
converted to the Visual Memory Index using the WRAML2 Software. The Visual 
Memory Index has a Reliability Coefficient of 0.89, which means that there is 89% 
confidence that that tests are measuring visual short-term memory.  
 
2.3.7                Attention/Concentration Tests 
To assess attention and concentration, two tests were administered, the Fingers/Window 
Test and the Number/Letter test.  Regarding the Fingers/Window Test, the tester pointed 
into windows (holes) on a card. The subjects observed the sequence in which the 
windows were pointed to and then were asked to repeat the sequence. This test had a 
maximum score of 24 points. As for the Number/Letter Test, the tester spoke numbers 
and letters in a particular order.  After the tester was done, the subjects were asked to 
repeat the numbers and letters in the same order. This test had a maximum score of 25 
points. Raw scores from the Fingers/Window Test and Number/Letter Test were scaled, 
combined, and converted to the Attention/Concentration Index using the WRAML 2 
Software. The Attention/Concentration Index has a Reliability Coefficient of 0.90, which 
means that there is 90% confidence that tests are measuring attention and concentration. 
A schematic of the tests and how they relate to the Screening Memory Index and the 
General Memory Index are indicated in Figure 7.  
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Fig. 7 Classification of WRAML 2 Memory Tests 
 
2.3.8 Compensation 
The subjects were compensated for their participation in the study with 
$25. They were also provided parking on Duquesne University Campus if needed.  
 
2.3.9                Statistical Analysis  
 The raw scores from the six memory tests were converted to standardized 
scores using the WRAML 2 Administration and Technical Manual.  Performance 
following treatment was compared to the scores of the placebo group to determine 
whether any change in memory performance occurred. Verbal Memory Index, Visual 
Memory Index, Attention Concentration Index, Screening Memory Index and General 
Memory Index were compared between the treatment groups (Choline 2 gm, Choline 2 
gm + Caffeine 25 mg, Choline 2 gm + Caffeine 50 mg, Choline 2 gm + Caffeine 100 mg 
and the placebo group). A one-way ANOVA was conducted to evaluate the effects of 
drug treatment on short-term memory and attention. The dependent variables were the 
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indices obtained from the raw scores of performance on the various memory tests.  The 
independent variable was the drug combinations/groups.        
Null Hypothesis (H0): The treatments had no effect on the short-term memory of health 
adult volunteers.  
Alternate Hypothesis (H1): The treatments alter the short-term memory of healthy adult 
volunteers.  
To test the hypothesis, we compared group means using one-way analysis 
of variance (non-parametric). A non-parametric Dunnett’s test was used to compare the 
mean of treatment groups against the placebo group. A D'Agostino-Pearson omnibus test 
was performed to confirm normal distribution. The null hypothesis was rejected if p < 
0.05.  The mean arterial blood pressure (MAP) was calculated using the formula:                                                      
Diastolic Pressure + 1/3 (Systolic Pressure – Diastolic Pressure)  
Mean arterial blood pressures were calculated for each individual within a group.  Mean 
MAPs were calculated for each treatment group.  Comparisons were made between 
treatment groups and placebo using one-way ANOVA.  Significance was defined as 
p<0.05. 
 
3.0             Analysis and Results  
3.1  Subject Demographics 
3.1.1               Age Distribution  
Subjects were recruited from around the city by advertisements on 
campus and flyers. Volunteers were phone/email screened prior to appointment to 
ensure that they met the exclusion criteria. For participation, the subject had to be 
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between 30 to 65 years of age. This was confirmed in the prescreening for each 
participant that called in. On the day of testing, the participants were assigned into 
one of the five treatment groups by random sampling. The data in table 4 below, 
shows mean age of individuals across treatment groups. The desired outcome was to 
see no significant difference in the mean age among groups. The results of ANOVA 
indicate no significant difference in the mean age among the different treatment 
groups. Also, the data for each group has a normal distribution.  
    
    Choline 2gm Choline 2 gm  
+     
Caffeine 
 25 mg 
Choline 2 gm  
+    
Caffeine 
 50 mg 
Choline 2 gm  
+  
Caffeine 100mg 
Placebo 
Mean Age (yrs) 
± SEM 
40.80±1.9 43.56±23 39.60±1.8 44.08±1.9 44.40±2.4 
Age Range 30-59 30-61 30-61 30-59 30-65 
Table 4. Age distribution of subject population  
 
Fig. 8. Mean age in treatment groups  
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3.1.2                Gender Distribution  
 The data in table 5 below indicate the number of males and females in 
each group. It was desired to have an equal number of male and female subjects in 
each group. Each treatment group has thirteen females and twelve males.  
     
    Choline 2gm 
Choline 2 gm  
+     
Caffeine 25 mg 
Choline 2 gm  
+    
Caffeine 50 mg 
Choline 2 gm  
+  
Caffeine 
100mg 
    
  Placebo 
Male      12       12        12 12 12 
Female      13      13        13       13      13 
Table 5. Gender distribution of subject population 
  
Fig. 9 Gender distribution across treatment groups  
   
  In summary, the analyses of the demographics indicate that the mean 
age of population was constant across the five treatment groups. Also, all groups had 
the same number of male and female subjects.  
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3.2                   Verbal Memory Index 
The Verbal Memory Index is a measure of verbal short-term memory. 
In order to test whether or not choline alone or in combination with caffeine enhanced 
verbal short-term memory, subjects were given the Story Memory Test and the 
Verbal Learning Test. Scores from these tests combined to give the Verbal Memory 
Index, which has been compared across treatments as shown in table 6 and fig. 10. 
The results of the ANOVA indicated significant differences between the treatment 
group in the Verbal Memory Index, F (4,124) = 5.469, p = 0.0004. The group that 
was administered Choline 2 gm + Caffeine 50 mg showed a significantly lower 
Verbal Memory Index compared to the placebo group indicating a decrease in 
memory function. The R squared was 0.15 which indicates that 15% of variance in 
the Verbal Memory Index was due to the treatment groups.  
 
     
    Choline 2gm 
Choline 2 gm  
+     
Caffeine 25 mg 
Choline 2 gm  
+    
Caffeine 50 mg 
Choline 2 gm  
+  
Caffeine 
100mg 
    
  Placebo 
Mean Verbal 
Memory 
Index± SEM 
98.12±2.9 104.1±3.1 *84.44±3.2 96.12±2.7 96.32±3.2 
Range 62-126 59-123 57-117 72-123 72-135 
*p < 0.05  **p< 0.01 ***p < 0.001  
Table 6. Scores of Verbal Memory Index 
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Fig. 10 Scores of Verbal Memory Index. Each bar represents the mean +/- SEM of 12-13 
subjects.  Data were analyzed by one-way ANOVA followed by a Tukey’s test. (*) Indicates 
p<0.05, (**) indicates p<0.01 and (***) indicates p<0.001 when compared to Placebo. . 
  The data in table 6 and fig. 10 above indicate that the group that 
administered Choline 2 gm + caffeine 50 mg had significantly lower performance in 
the verbal memory tests as compared to placebo indicating that this group has 
impaired verbal short-term memory. Also, the group that administered Choline 2 gm 
+ caffeine 25 mg shows a trend towards increase in verbal short-term memory as 
compared to placebo.  
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*p < 0.05  **p< 0.01 ***p < 0.001
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3.3                   Visual Memory Index 
             The Visual Memory Index is a measure of the visual short-term 
memory. In order to test whether or not choline alone or in combination with caffeine 
enhanced memory associated with visual memory, subjects were given the Picture 
Memory Test and the Design Memory Test. Scores from these tests combined to give 
the Verbal Memory Index, which has been compared across treatments as shown in 
table 7 and fig. 11.  The results of the ANOVA indicated significant differences 
between the treatment groups in the Visual Memory Index. F(4,124) = 8.818, p < 
0.0001. The group administered Choline 2 gm + Caffeine 25 mg showed a 
significantly higher Visual Memory Index when compared to the Placebo group.  The 
R squared was 0.22 which indicates that 22% of the variance in the Visual Memory 
Index was due to the treatment groups. 
 
Table 7. Scores of Visual Memory Index 
     
    Choline 2gm 
Choline 2 gm  
+     
Caffeine 25 mg 
Choline 2 gm  
+    
Caffeine 50 mg 
Choline 2 gm  
+  
Caffeine 
100mg 
    
  Placebo 
Mean Visual 
Memory 
Index ± SEM 
 110.3±4.2 **123.8±2.8 95.16±3.9 107±3.1 106.3±2.8 
Range 67-144 91-145 63-141 76-144 82-134 
*p < 0.05  **p< 0.01 ***p < 0.001 
  33 
  
Fig. 11   Scores of Visual Memory Index. Each bar represents the mean +/- SEM of 12-13 
subjects.  Data were analyzed by one-way ANOVA followed by a Tukey’s test. (*) Indicates 
p<0.05, (**) indicates p<0.01 and (***) indicates p<0.001 when compared to Placebo. . 
The data in table 7 and fig. 11 above indicate that the group that 
administered Choline 2 gm + caffeine 25 mg had significantly higher performance in 
the visual memory tests as compared to placebo indicating that this group has 
enhanced visual short-term memory. Also, the group that administered Choline 2 gm 
+ caffeine 50 mg shows a trend towards decrease in visual short-term memory as 
compared to placebo. 
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3.4                  Attention/Concentration Index 
 In order to test whether or not choline alone or in combination with 
caffeine enhanced attention/concentration, subjects were given the Fingers Window 
Test and the Number Letter Test. Scores from these tests combined to give the 
Attention/Concentration Index, which has been compared across treatments. The data 
are shown in table 8 and fig. 12. The results of the ANOVA indicated a significant 
treatment effect (p < 0.05) in the Attention/Concentration Index, F (4,119) = 4.863, p 
= 0.0012. The group administered Choline 2 gm + Caffeine 50 mg showed a 
significantly lower Attention/Concentration Index compared to the Placebo group. 
The R squared was 0.15 which indicates that 15% of the variance in the 
Attention/Concentration Index was due to the treatment. 
 
     
    Choline 2gm 
Choline 2 gm  
+     
Caffeine 25 mg 
Choline 2 gm  
+    
Caffeine 50 mg 
Choline 2 gm  
+  
Caffeine 
100mg 
    
  Placebo 
Mean 
Attn/Conc ± 
SEM 
109.1±3.9 118.3±3.1  *99±3.3 110±1.9 110.9±3.3 
Range       59-141          88-145        57-123      97-128     70-141 
*p < 0.05  **p< 0.01 ***p < 0.001 
Table 8.  Scores on Attention/Concentration Index  
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Fig. 12   Scores on Attention/Concentration Index . Each bar represents the mean +/- SEM of 12-
13 subjects.  Data were analyzed by one-way ANOVA followed by a Tukey’s test. (*) 
Indicates p<0.05, (**) indicates p<0.01 and (***) indicates p<0.001 when compared to 
Placebo.  
 
The data above in table 8 and fig. 12 indicate that the group that 
administered Choline 2 gm + caffeine 50 mg had significantly lower performance in the 
attention/concentration tests as compared to placebo indicating that this group has 
impaired attention/concentration. Also, the group that administered Choline 2 gm + 
caffeine 25 mg shows a trend towards increase in attention/concentration as compared to 
placebo.  
 
3.5                   Screening Memory Index 
  Screening memory index is obtained after scaling raw scores from the 
verbal and visual memory tests. Unlike, the General Memory Index, the Screening 
C
ho
C
ho
+2
5C
af
f
C
ho
+5
0C
af
f
C
ho
+1
00
C
af
f
Pl
ac
eb
o
80
90
100
110
120
130
Attention/Concentration Index
*
S
ta
n
d
a
rd
iz
e
d
 S
ca
le
 
*p < 0.05  **p< 0.01 ***p < 0.001
  36 
Memory Index does not take into account the effect of attention/concentration. Since 
attention/concentration is a component that only governs the amount of stimuli 
received, it is not considered memory. Rather, it regulates memory formation. The 
rationale for using this index is to compare the effect of the treatments independent of 
the scores obtained from the attention/concentration tests. See below in table 9 and 
figure 13.  The results of the ANOVA indicated a significant treatment effect (p < 
0.05) in the Screening Memory Index, F (4,124) = 9.812, p < 0.0001. The R squared 
value was 0.2465 which indicates that 24% of the variance in the Screening Memory 
Index was due to the treatment. To further assess the differences among groups, we 
conducted pair-wise comparisons between the means using Tukey’s test, a multiple 
comparisons procedure that assumes equality of variances. Bartlett’s test for equal 
variances indicated that the variances among the groups did not differ significantly. 
Based on the results of the Tukey’s test, we determined that the group that was given 
the Choline 2 gm + Caffeine 50 mg treatment had significantly lower scores whereas 
the group that was administered the Choline 2 gm + Caffeine 25 mg had significantly 
higher scores than the placebo group.  
     
    Choline 2gm 
Choline 2 gm  
+     
Caffeine 25 mg 
Choline 2 gm  
+    
Caffeine 50 mg 
Choline 2 gm  
+  
Caffeine 
100mg 
    
  Placebo 
Mean 
Screening 
Memory 
Index± SEM 
   104.9±3.8   ***116.4±2.6 *87.64±3.5 101.5±3.0 101.2±3.1 
Range         60-141        87-137        55-127      69-139     79-137 
*p < 0.05  **p< 0.01 ***p < 0.001  
Table 9. Scores on Screening Memory Index 
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Fig.13  Scores on Screening Memory Index. Each bar represents the mean +/- SEM of 12-13 
subjects.  Data were analyzed by one-way ANOVA followed by a Tukey’s test. (*) Indicates 
p<0.05, (**) indicates p<0.01 and (***) indicates p<0.001 when compared to Placebo.  
 
The data above indicate that the group administered Choline 2 gm + 
caffeine 50 mg had a significantly lower Screening Memory Index as compared to 
placebo indicating that this group has impaired verbal short-term memory and visual 
short-term memory. Also, the group that was administered Choline 2 gm + caffeine 25 
mg had a significantly higher Screening Memory Index as compared to placebo 
indicating that this group had enhanced verbal short-term memory and visual short-term 
memory. Other treatment groups were not significantly different from placebo.  
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3.6                  General Memory Index 
The General Memory Index was obtained after scaling raw scores from the 
verbal and visual memory tests and the attention/concentration tests. This index gives a 
reflection of the overall short-term memory performance of the individual. See table. 10 
and fig. 14. The results of the ANOVA indicated a significant treatment effect (p < 0.05) 
in the General Memory Index, F (4,119) = 13.32, p < 0.0001. The R squared was 0.32 
which indicates that 32% of the variance in the General Memory Index was due to the 
treatments. To further assess the differences among groups, we conducted pair-wise 
comparisons among the means using Tukey’s test, a multiple comparisons procedure that 
assumes equality of variances. Bartlett’s test for equal variances indicated that the 
variances among the groups did not differ significantly. Based on the results of the 
Tukey’s test, we determined that the group that was given the Choline 2 gm + Caffeine 
50 mg treatment had significantly lower scores than the Placebo group whereas the group 
that was administered the Choline 2 gm + Caffeine 25 mg had significantly higher scores 
than the Placebo group.  
 
     
    Choline 2gm 
Choline 2 gm  
+     
Caffeine 25 mg 
Choline 2 gm  
+    
Caffeine 50 mg 
Choline 2 gm  
+  
Caffeine 
100mg 
    
  Placebo 
Mean 
General 
Memory 
Index± SEM 
 107.2±3.9  ***116.1±2.3 *82.76±3.3 100.3±2.5 101.3±2.7 
Range       55-140        102-143          55-114      75-130     87-139 
*p < 0.05  **p< 0.01 ***p < 0.001 
Table 10. Scores on General Memory Index 
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Fig. 14 Scores on General Memory Index. Each bar represents the mean +/- SEM of 12-13 
subjects.  Data were analyzed by one-way ANOVA followed by a Tukey’s test. (*) Indicates 
p<0.05, (**) indicates p<0.01 and (***) indicates p<0.001 when compared to Placebo. . 
 
 
Fig. 15 Comparison of General Memory Index between Male and Female Subjects. Each bar 
represents the mean +/- SEM of 12-13 subjects.  Data were analyzed using a t- test.  
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The data above indicate that the group that administered Choline 2 gm + 
caffeine 50 mg had a significantly lower General Memory Index as compared to placebo 
indicating that this group had impaired overall short-term memory. Also, the group that 
administered Choline 2 gm + caffeine 25 mg had a significantly higher General Memory 
Index as compared to placebo indicating that this group had an enhanced overall short-
term memory. Other treatment groups were not significantly different from placebo.  
Furthermore, there is evidence for suggesting a beneficial role of estrogen 
on memory performance (102). Hence, we compared the short-term memory between 
male and female subjects in each group to observe for any differences based on gender. 
However, no significant difference was observed in the General Memory Index between 
male and female subjects.  
 
3.7                 Blood Pressures and Heart Rate  
                      There is evidence suggesting that caffeine may increase blood pressure and 
heart rate. Thus, one of the exclusion criteria for participation in the study was for the 
subject to be free from a high blood pressure condition. To ensure this, blood pressure 
and heart rate were measured, when the patient came in. 30 mins after capsule 
administration, blood pressure and heart rate were measured again to monitor for 
potential side effects from the treatment (Fig.16, 17).  
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Fig. 16 Comparison of Mean Arterial Pressure at 0 mins (MAP1) and 30 mins (MAP2) after 
Capsule Administration. Each bar represents the mean +/- SEM of 12-13 subjects.  Data were 
analyzed by paired t-test to test for differences within individuals over time. 
 
                A paired t-test was used to compare the mean arterial pressures. MAP1 was 
obtained from the data collected before the subjects were administered the capsules, 
whereas MAP2 was the data recorded 30 min after capsule administration. No significant 
differences in MAP1 and MAP2 were observed for any of the treatment groups.  
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Fig. 17. Comparison of Heart Rate at 0 mins (HR1) and 30 mins (HR2) after Capsule 
Administration. Each bar represents the mean +/- SEM of 12-13 subjects.  Data were analyzed by 
paired t-test to test for differences within individuals over time.  
 
            Similarly, the results of the t-test indicated that there was no significant 
difference in the heart rate measured before and 30 min after capsule administration. 
 
3.8                   Data For Groups  
  To assess the performance of each individual in three core indices, Verbal 
Memory Index, Visual Memory Index and Attention/Concentration Index, we plotted a 
trend graph for every group. For every individual, we plotted the difference between the 
individual subject’s score on the index and the mean score for the placebo group on that 
index. This allowed to us to compare the score of each individual with the placebo group 
mean for that index. Following this, a trend line was plotted across the distribution among 
the 25 subjects. The trend line shows a positive difference or negative difference from the 
placebo (0 line). This would correspond to overall enhanced performance, impaired 
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performance or no effect as compared to placebo. Such a plot removes errors that may 
occur on comparing means among groups.  
 
3.8.1               Choline 2 gm  
           The plot in fig.18 shows the difference of each individual’s score in the 
Choline 2 gm + group on the three indices Verbal Memory Index, Visual Memory Index 
and Attention/Concentration Index, from the mean score of placebo group on the each of 
the indices.  
 
Fig. 18 Individual Subject Data- Choline 2 gm  
The trend lines on the plot are on the positive side of 0, but very close 
to 0. This indicates that on the whole, all individuals performed better than the 
placebo on the memory tests, but this difference was very small.   
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3.8.2  Choline 2 gm + Caffeine 25 mg  
  The plot in fig.19 shows the difference of each individual’ score in the 
Choline 2 gm + Caffeine 25 mg group on the three indices Verbal Memory Index, Visual 
Memory Index and Attention/Concentration Index, from the mean score of placebo group 
on the each of the indices.  
 
Fig. 19 Individual Subject Data- Choline 2 gm + Caffeine 25 mg  
 
The trend lines on the plot are on the positive side of 0. This indicates that on 
the whole, all individuals performed better than the placebo on the memory tests.  
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3.8.3               Choline 2 gm + Caffeine 50 mg  
           The plot in fig.20 shows the difference of each individual’s score in the 
Choline 2 gm + Caffeine 50 mg group on the three indices Verbal Memory Index, Visual 
Memory Index and Attention/Concentration Index, from the mean score of placebo group 
on the each of the indices.  
 
 
Fig. 20 Individual Subject Data- Choline 2 gm + Caffeine 50 mg 
 
The trend lines on the plot are on the negative side of 0. This indicates 
that on the whole, all individuals performed lower than the placebo on the memory 
tests.  
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3.8.4               Choline 2 gm + Caffeine 100 mg  
           The plot in fig.21 shows the difference of each individual’s score in the 
Choline 2 gm + Caffeine 100 mg group on the three indices Verbal Memory Index, 
Visual Memory Index and Attention/Concentration Index, from the mean score of 
placebo group on the each of the indices.  
 
Fig. 21 Individual Subject Data- Choline 2 gm + Caffeine 100 mg  
 
The trend lines on the plot are on the positive and negative side of 0. 
This indicates that this group has a set of subjects that performed better than the 
placebo and a group that did worse than placebo on the memory tests. Thus, this 
group had a set of responders and non-responders.  
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4.0                Discussion  
         Memory is a complex behavioral phenomenon that is influenced by 
various factors both within an individual as well as between individuals. Memory is a 
four-step process. The first step is gathering information from the surroundings followed 
by consolidation of this information. This consolidated information is then stored for the 
process of retrieval, which is re-accessing the stored information as required. The process 
of gathering information from the surrounding occurs through senses. For example, 
things we see, smell, hear and touch become memories. A third element of this process is 
attention and/or concentration, which functions as a filter to control the amount of 
information gathered at a time. Variation in any of these components leads to differences 
in the quality and quantity of information processed. This creates differences in the 
memory capacity between individuals. For example, some individuals are better auditory 
learners while others are better visual learners. The variable aspect of memory function 
makes it difficult to measure and quantify memory.  
        The current study tests the effect of two commonly consumed dietary 
components, caffeine and choline, on short-term memory in humans. Short-term memory 
is memory that is stored for a few minutes to a few hours. Our study used a psychometric 
instrument called the Wide Range Assessment of Memory and Learning 2 to measure the 
performance. This is a popular instrument used commonly to measure short-term memory 
in humans. It is standardized and validated across the nationwide population. The 
WRAML 2 has six core tests. Four of these tests are designed to measure short-term 
visual and verbal memory, and two tests measure attention/concentration. Finally, this 
test gives quantitative information about the overall short-term memory in humans.  
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External factors that were controlled for the trial included the tester, room 
of testing and time of testing. This was done to control for variances that may occur due 
to tester differences such as speed of speaking, volume of speech and accent, which are 
not controlled by the WRAML 2. Time of day may influence performance on memory 
tests due to the sleep-wake cycle; thus, all subjects were tested between 12 pm and 5 pm. 
All groups contained an equal number of male and female participants to control for the 
effect of gender and related factors on memory performance. The study was double 
blinded, which ruled out subjective factors for both the tester and the participants. The 
doses of the experimental drugs (caffeine and choline) used for this study were regular 
dietary doses. One hundred mg, which was the maximum dose of caffeine, is present in a 
cup of coffee (80) and 2 gm of choline is how much you can find in 4 – 5 whole large 
eggs (81).  
The subjects were administered six memory tests that were designed to 
measure verbal short-term memory, visual short-term memory and 
attention/concentration. The scores of combined from the tests provided an overall 
assessment of each subject’s short-term memory as quantified by the Screening Memory 
Index and General Memory Index. The General Memory Index is a quantitative measure 
of the short-term memory in humans whereas the Screening Memory Index measures 
only the visual and verbal short-term memory, excluding the attention/concentration 
component.  
The WRAML 2 is validated across the nationwide population. The mean 
of the nationwide population is 100 and standard deviation is 15 for all the indices. The 
placebo group scores were not statistically different from this population mean of 100 for 
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any of the indices. This result confirms the normal distribution of the scores of subjects in 
the placebo group. It also confirms that the WRAML 2 was administered effectively.   
For the treatment groups administering Choline 2 gm and Choline 2 gm + 
Caffeine 100 mg, there was no significant effect of the drugs on performance for any of 
the memory tests as compared to the placebo group. This result is consistent with two 
previous trials conducted with this combination in humans. When we analyzed the scores 
of each individual in the Choline 2 g, we observed that all subjects were non-responders 
to the treatment (Fig.X).  However, for the subjects in the Choline 2 gm + Caffeine 100 
mg, some were responders and some were non-responders (Fig.X).  
The group which administered Choline 2 gm + Caffeine 50 mg had 
significantly lower scores on the Verbal Memory Index, Attention/Concentration Index, 
Screening Memory Index and General Memory Index, compared to the placebo group. 
This group had lower scores than placebo for the Visual Memory Index. The group 
administered Choline 2 gm + Caffeine 25 mg had significantly higher scores on the 
Visual Memory Index, Screening Memory Index and General Memory Index compared 
to the Placebo group. This group had a trend of increase for the Verbal Memory Index 
and Attention/Concentration Index.   
 Based on the data, we observed that the level of attention affects 
performance on memory tests. The Choline 2 gm + Caffeine 25mg has higher 
attention/concentration (although not significantly different) than the placebo, the 
Choline 2 gm + Caffeine 50 mg has significantly lower attention/concentration, and the 
Choline 2 gm and Choline 2 gm + Caffeine 100 mg has no difference in 
attention/concentration from placebo. The scores on the verbal and visual indices 
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correspond to the scores in tests for attention/concentration. Thus we can conclude that 
the combination of caffeine and choline is affecting attention/concentration in a dose-
dependent fashion, which is, in turn, influencing performance on memory tests. This is 
reconfirmed by the results on the Screening Memory Index, which has the same pattern 
of performance as the General Memory Index and Attention/Concentration Index across 
groups.  
 
 
 
 
 
 
 
Table 11 Arrows indicated increase or decrease in performance as compared to placebo. – 
Indicates no effect.  
                            
 As shown in Table. 11 we found that different dose combinations of 
caffeine and choline affect different components of memory differently. In the past, 
several studies were conducted to examine the effect of caffeine on short-term memory. 
Previous studies of caffeine’s effect on human short-term memory showed either no 
effect on short-term memory performance (82,83), improved short-term memory 
performance (84,85) or impaired short-term memory (86,87) in animals and humans.  
A number of studies examined the effect of caffeine on human behavior 
(88-90), and reported beneficial effects of caffeine on memory performance. Schmitt 
A.J., et al., 2003 (91) demonstrated that caffeine, in low doses, did not affect memory 
function and attention in middle-aged and elderly. Reidal et. al.,1995 (12) demonstrated 
 Cho 2gm Cho 
2gm+Caff 
25 mg 
Cho 
2gm+Caff 
50mg 
Cho 
2gm+Caff 
100mg 
VRMI - -  - 
VMI -         - - 
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Index 
- -  - 
SMI  -   - 
GMI -   - 
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that 250 mg of caffeine attenuates scopolamine-induced memory impairments. Rogers 
P.J.  and Dernoncourt C., 1998 (94) demonstrates that regular caffeine consumption could 
improve short-term memory by testing the effect of caffeine on recall tasks. However, 
Terry and Phifer B, 1986 (95), show that 100 mg of caffeine significantly reduces the 
recall of words in an AVLT (Auditory-Verbal Learning Test) test conducted on 33 
students. Erikson et al.,1985 (96) show that caffeine impaired memory in females who 
were administered 2 mg/kg and 4 mg/kg of caffeine. Thus, our study is consistent with 
the findings that different doses of caffeine can affect memory differently. Our goal was 
to discover the optimal dose combination of caffeine and choline that improved memory.  
The effect of the combination of caffeine and choline is a result of a 
complex interaction between the dose, subject and the task.  The WRAML2 allowed the 
comparison of the effects of several combinations of caffeine and choline on the 
attention/concentration component exclusively. The scores on the individual memory 
components and attention/concentration were also analyzed separately. This was done 
since attention/concentration is not considered memory, rather it the component that 
governs the extent of memory formation. The Choline 2 gm + Caffeine 25 mg improved 
Visual Memory Index and Attention/Concentration Index as compared to placebo. 
However, Choline 2 gm + Caffeine 50 mg significantly decreased the Verbal Memory 
Index and the Attention/Concentration Index. Thus, we can conclude that the 
combination of caffeine and choline is affecting attention, which is, in turn, affecting 
verbal and visual memory. Also, with higher attention, visual memory is enhanced more 
than verbal memory, as in the case of Choline 2 gm + Caffeine 25 mg group and with 
lower attention, verbal memory is impaired greater than the visual memory as in the case 
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of Choline 2 gm + Caffeine 50 mg group. This could be due to a practical reason that it is 
easier to register visual than auditory information as may be observed in daily life.  
Several studies have indicated that caffeine, in doses as low as 30 mg can 
have an effect on mood and cognition. (97-99).  Johnson et. al.,1992 (68) demonstrated 
that caffeine potentiates the enhancement by choline of striatal acetylcholine release in rat 
brain. Thus, the enhanced memory performance at the Choline 2 gm + Caffeine 25 mg 
may be due to increased acetylcholine release at this dose combination. Choline 2 gm + 
Caffeine 100 mg did not show an improvement in overall memory function. This is 
consistent with the study conducted by Li Li at Duquesne University, “ The effect of 
Caffeine and Choline on Short-term Memory, a clinical study”, in 1996 and the follow-up 
by Dr.Jamie McConaha.  These studies used the same dose combination, Choline 2 gm + 
Caffeine 100 mg that found no improvement in WMS-R tests. Also, in the same trial, 
Choline 2 gm alone showed no significant improvement in digit span backward or 
forward, digit symbol, or associate learning tests as compared to placebo. This is also 
consistent with the findings of our study, where the Choline 2 gm alone showed no 
significant improvement as compared to the placebo.  
The Choline 2 gm + Caffeine 50 mg dose however, did show an 
impairment in memory. Johnson et al., 1992 (68) demonstrated that caffeine and choline 
could be synergistic in certain dose combinations. A possible explanation for impairment 
of memory at this dose combination could be side effects of caffeine such as having the 
jitters or anxiety due to synergism with this combination, as opposed to an additive effect 
at other doses. Another possibility could be due to an activation of a negative feedback 
mechanism at higher doses of choline and caffeine. Thus more Ach would be taken up by 
  53 
the presynaptic cholinergic neurons by receptors such as the M2 muscarinic receptors. 
Since these are Gi coupled, they may in turn decrease the release of Ach. This is also 
observed for the Choline 2 gm + Caffeine 100 mg group, which had a set of non-
responders. This hypotheses is supported by the data for the Attention/Concentration 
Index, which was significantly reduced by the Choline 2 gm + Caffeine 50 mg compared 
to the placebo.  However, objective measures that include a measurement of blood ACh 
levels would support or refute this hypothesis. Also, this study is consistent with the 
results of a previous study conducted by graduate student Devon Marcusun and Dr. 
David Johnson who found that when doses of combined caffeine and choline were 
reduced, the reversal of amnesia caused by scopolamine in rats was greater as compared 
to placebo and as compared to higher combination caffeine and choline doses.  
Another important finding of the study was that gender did not have any 
influence on test performance. We observed no significant difference between the scores 
of male and female subjects on the short-term memory tests. However, we did not control 
for factors such as stages of menopause in women, which may have an influence on 
memory due to estrogen levels. Thus, no conclusion can be made.  
The use of six different tests allowed us to compare the effect of each dose 
on different memory functions i.e. visual and verbal short-term memory as well as the 
attention/concentration. It was interesting to find that the different dose combinations of 
caffeine and choline had very different effects on the short-term visual and verbal 
memory of healthy adult volunteers. This study confirms that caffeine effects on memory 
function are dose dependent. The most important result of the study is the identification 
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of the combination of Choline 2 gm + Caffeine 25 mg as a promising candidate for a 
potential memory supplement.  
In the future, it would be worthwhile to study the effect of the dose 
Choline 2 gm + Caffeine 25 mg on a cognitively impaired adult population.  If this 
combination is in fact beneficial in improving memory, it may become a potential 
candidate for conditions of cognitive dementia. 
 
5.0                Conclusions  
 In conclusion, choline, by itself, was not effective for improving short-
term memory at the 2 gm dose. However, combinations of choline (2 g) with low doses 
of caffeine (25 mg) facilitated visual short-term memory.  When the dose of caffeine was 
increased 2 fold to 50 mg, this combination no longer enhanced memory but impaired it.  
Even more intriguing is the finding that a four-fold increase of caffeine from 25 mg to 
100 mg did nothing to memory when compared to placebo.  These data suggest that 
caffeine and choline combinations can facilitate short-term memory, but effectiveness is 
dependent on the dosage of choline and caffeine within the combination.  
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APPENDIX A  
 
DUQUESNE UNIVERSITY 
600 FORBES AVENUE      PITTSBURGH, PA 15282 
 
 
 
 
CONSENT TO PARTICIPATE IN A RESEARCH STUDY 
 
 
TITLE: The Effect of Caffeine and Choline on Short-term 
Memory 
 
INVESTIGATOR:              Natasha Nagrecha 
                                                            425, Mellon Hall 
                           412-396-6367 
                                     
                                                            Dr. David Johnson 
                                                            408A Mellon hall 
                                                            412-396-5952 
 
                                                            Dr. Vincent Giannetti 
                                                            310 Bayer Learning Center 
                                                            412-396-6379 
  
ADVISOR:                           Dr. David Johnson 
                                                            408A Mellon hall 
                                                            412-396-5952 
 
SOURCE OF SUPPORT: This study is being performed as partial fulfillment 
of the requirements for the Masters degree in 
Pharmacology at Duquesne University. The 
research project will be funded by the school of 
pharmacy. 
 
PURPOSE: The intent of this study is to determine the effect of     
caffeine (a substance found in products such as tea, 
coffee etc) and choline  (a dietary substance found 
in certain food products such as eggs) can enhance 
short-term memory.  The study also seeks to 
determine the optimal combination of caffeine and 
choline that could provide the greatest benefit. 
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YOUR PARTICIPATION:          The study will consist of one visit. The testing site 
will be an assigned room on Duquesne University’s 
campus. You will be given a prior appointment in 
the beginning of the study. 
  
You will be asked to refrain from consuming any 
medication, food or drink containing caffeine for at 
least eight hours before your scheduled 
appointment. If need be, your appointment can be 
scheduled in the morning hours.    
 
On the day of your scheduled appointment, you will 
arrive at the testing site 15 minutes prior to your 
scheduled time. You will be given a unique 
identifier number that serves to protect your 
privacy. Before beginning, the procedure that will 
take place will be explained and your pulse and 
blood pressure will be recorded.   
 
On your visit, you will be given a capsule. The 
capsules will contain either 0 mg of caffeine and 
2gm of choline, 25 mg of caffeine and 2gm of 
choline, 50 mg of caffeine and 2gm of choline, 100 
mg of caffeine and 2gms of choline or capsule 
containing neither drug. You will not be able to tell 
which capsule you are taking since they will be 
formulated in such a way as to make it impossible 
to tell the difference between them by taste, color or 
odor. Thirty minutes after taking the capsule you 
will have your blood pressure and pulse rechecked 
and you will be administered six memory tests.  
 
The tests will be conducted forty minutes after 
taking the capsules. The first test is the Story 
Memory Test. A short story will be read out to you 
and you will be asked to recall as much of the story 
as possible. The second test is the Verbal Learning 
Test. You will be read a list of simple words 
following which you will recall as many of them as 
possible. The third test is the Design Memory Test. 
You will be presented with five cards with 
geometric figures on them. After looking at them, 
you will have to redraw what you remembered from 
the card you just saw. The fourth test is the Picture 
Memory Test. You will be shown a picture that you 
have to see carefully until it is taken away. The fifth 
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test is the Finger Windows test. You will be shown 
a card with holes. The tester will point a pencil at 
the holes in a specific order. You have to observe 
and repeat the same order. The last test is Number 
letter test. The tester will read numbers and letters 
to you in a particular sequence. You will be asked 
to repeat the numbers and letters in the same 
sequence.    
 
RISKS AND BENEFITS: The intent of the study is to discover a new drug 
therapy that could improve memory. Caffeine and 
choline are drugs that are available over-the-
counter. They will be administered in doses that are 
commonly found in a normal diet. Choline is a 
dietary component found in food products such as 
eggs, milk, peanuts etc. It is found in commercial 
products such as Advanced Ginkgo Smart® which 
is used to improve memory. Choline may have 
possible side effects such as stomach upset, 
salivation, loss of appetite, dizziness, vomiting, 
nausea, sweating, diarrhea, fish body odor etc. In 
case of allergic reaction to choline you may 
experience chest tightness or skin rashes. There is 
no standard dose for choline but upper limit for 
intake in adults is 3.5 grams per day. However, due 
to its mild nature, excess intake is likely to pose no 
risk significant risk of adverse effects.  The doses of 
caffeine used in this study will be 0mg, 25mg, 
50mg and 100mg.  Caffeine is an ingredient found 
in various food products such as coffee, tea, beans, 
etc. It is also present in certain prescription 
medication along with commercial products such as 
soda. Caffeine acts as a mild stimulant on the 
central nervous system. It causes sleep warding off 
and increases alertness. It may cause a mild increase 
in the heart rate and blood pressure. Although these 
are transient effects, your blood pressure and heart 
rate will be monitored throughout the study.   
                                                            The dose of choline used in this study will be 2gm. 
 
 
COMPENSATION: To compensate for your time you will be paid $25.        
You will also be reimbursed for parking on         
Duquesne University campus.  
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CONFIDENTIALITY: The trials are designed in such a way that neither 
the memory tester nor the person giving the capsule 
will know which drug you have taken or what your 
name is. These facts will remain confidential until 
the end of the trials. When the results are analyzed, 
your performance will be evaluated using your 
number, not your name. Your name will not be 
linked to your individual performance in any report 
or communication resulting from this study. If some 
reason develops to reveal your individual data, your 
confidentiality will still be maintained unless you 
give your express written permission.  
 
RIGHT TO WITHDRAW: You are under no obligation to participate in this 
study.  You are free to withdraw your consent to 
participate at any time. Your decision to end your 
involvement will result in no negative consequences 
to you.  Also, you are free to ask questions during 
any point throughout the study. 
 
SUMMARY OF RESULTS: A summary of the memory results of this research 
will be supplied to you, only upon request. 
 
VOLUNTARY CONSENT: I have read the above statements and understand 
what is being requested of me.  I also understand 
that my participation is voluntary and that I am free 
to withdraw my consent at any time, for any reason.  
On these terms, I certify that I am willing to 
participate in this research project. 
 
 I understand that should I have any further 
questions about my participation in this study, I 
may call Natasha Nagrecha, Dr.David Johnson and 
Dr. Paul Richer, Chair of the Duquesne University 
Institutional Review Board (412-396-6326).   
 
 
 
 
____________________________    ________________________ 
Participant's Signature      Date 
 
 
____________________________               _______________________ 
Researcher's Signature      Date 
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  SCREENING PROCEDURE 
 
 
SECTION I 
                                                 Personal Information 
 
 
1. Name: 
2. Address:  
3. Phone Number:  
4. Social Security Number: 
5. Date of Birth: 
6. Age: 
7. Sex: 
8. In case of emergency: 
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SECTION II 
 
Medical History 
 
 
          Check if Yes 
 
1. Diabetes       _______________________ 
2. Thyroid disease       _______________________ 
3. Heart or cardiopulmonary disease _______________________ 
4. High blood pressure or hypertension    _______________________ 
5. Breathing difficulties i.e. asthama                                                   _______________________ 
6. Liver disorder                                      _______________________ 
7. Cancer        _______________________ 
8. Kidney or bladder disorder       _______________________ 
9. Epilepsy or seizures        _______________________ 
10. Recent surgery                     _______________________ 
11. Pregnancy or breast feeding       _______________________ 
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SECTION III 
            
                                                 Personal and Medical History 
 
            Check if YES  
 
1. Current prescription medical use  
(dose, duration)                
_______________________                           
2. Regular or current nonprescription or  
OTC medical use (cough, cold, antacids etc)                        
_______________________ 
3. Vascular or Blood disorders                           
_______________________ 
4. Allergies                                                                                                   
_______________________ 
5. Gastrointestinal disorders                                                                         
_______________________ 
6. Psychiatric disorder                                                                                  
_______________________ 
7. Endocrine disorder                                 
_______________________ 
8. Neurological disorder                           
_______________________ 
9. Mucoskeletal disorder                            
_______________________  
10.  Tobacco use                
_______________________ 
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11. Caffeine per day  
(Cups or glasses)                                                                                      
_______________________               
12. Recreational drug and alcohol use per week(Glasses)                             
_______________________ 
13. Comments                                  
_____________________________________________________________________ 
 
Investigator :     Signature of subject: 
Date:  
Signature: 
 
Data Collection Form  
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APPENDIX B 
Table.1.1 Age Distribution of Population 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
     
 
 
            I       II    III      IV  V 
39 61 38 47 56 
31 35 30 31 30 
51 48 49 40 57 
53 55 32 33 55 
37 30 36 30 57 
30 34 61 40 45 
55 38 43 55 57 
54 53 37 30 51 
43 50 41 52 45 
48 30 51 35 34 
49 31 51 59 31 
52 37 44 53 30 
59 34 30 41 42 
50 60 37 58 42 
37 60 31 48 33 
44 30 30 49 55 
31 44 54 42 65 
31 54 47 34 30 
30 60 36 49 36 
32 59 30 31 41 
32 31 40 49 58 
37 39 53 51 37 
33 31 29 37 44 
39 55 30 56 47 
39 61 38 47 56    
I    = Choline 2 gm  
II  = Choline 2 gm + Caffeine 25 mg 
III = Choline 2 gm + Caffeine 50 mg  
IV = Choline 2 gm + Caffeine 100 mg 
V  = Placebo 
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Table.1.2          Subject Gender Distribution  
 
 Male Female 
Cho 12 13 
Cho+25Caff 12 13 
Cho+50Caff 12 13 
Cho+100Caff 12 13 
Placebo 12 13 
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Table.2.1         Raw scores for Choline 2 gm group 
 
 
 
 
 
 
 
 
    Subject # 
      Story    
Memory 
 Design  
Memory 
     Verbal       
Learning 
 Picture     
Memory 
       Number 
Letter 
  Fingers 
Window 
1 40 53 44 36   
10 54 34 36 21 16 22 
17 35 38 38 42 23 24 
21 38 38 33 27 17 21 
33 58 47 51 32 17 25 
38 42 54 27 26 16 16 
42 49 39 38 22 18 24 
45 23 26 33 19 11 24 
49 54 56 34 22 21 24 
52 25 34 17 26 13 15 
72 63 25 32 33 12 16 
73 10 19 16 14 8 9 
74 62 49 26 33 10 15 
78 41 45 41 42 13 24 
79 41 56 40 29 19 19 
80 56 27 30 21 15 16 
81 51 54 39 40 11 25 
86 36 51 37 34 20 25 
96 30 45 30 26 21 25 
100 58 57 56 41 19 25 
112 52 51 50 29 19 18 
117 16 22 34 11 14 24 
118 32 49 40 31 19 25 
121 39 26 36 32 13 17 
122 39 56 47 27 15 25 
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Table.2.2         Raw scores for Choline 2 gm + Caffeine 25 mg group  
 
 
 
 
 
 
 
    Subject # 
      Story    
Memory 
      Design 
Memory 
     Verbal       
Learning 
 Picture     
Memory 
       Number 
Letter 
  Fingers 
Window 
3 28 24 31 21   
9 49 46 31 36 11 18 
14 45 40 43 44 12 22 
23 53 38 45 35 17 16 
25 37 48 39 29 19 25 
30 46 51 36 27 17 20 
37 36 48 37 38 19 22 
56 56 39 46 29 13 17 
57 52 39 30 29 16 21 
59 51 58 43 32 24 24 
60 60 54 50 43 21 22 
67 11 45 38 17 19 25 
69 15 60 16 36 24 24 
70 50 42 35 34 17 20 
77 55 43 43 38 22 25 
82 31 58 45 43 18 24 
84 52 47 44 41 13 24 
90 31 52 34 42 17 17 
97 39 47 39 37 19 24 
98 35 39 38 35 16 18 
107 49 54 40 34 22 25 
108 56 41 40 35 15 25 
109 60 58 53 29 24 25 
119 54 29 46 28 14 25 
120 63 56 38 37 19 25 
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Table.2.3     Raw scores for Choline 2 gm + Caffeine 50 mg group 
 
 
 
 
       
 
 
 
    Subject # 
      Story    
Memory 
      Design 
Memory 
     Verbal       
Learning 
 Picture     
Memory 
       Number 
Letter 
  Fingers 
Window 
5 55 31 49 33   
11 23 40 18 16 11 8 
12 33 32 45 38 16 16 
19 27 54 38 29 14 16 
27 38 53 24 36 20 16 
28 44 52 34 36 14 12 
29 39 33 33 33 15 18 
32 24 45 38 30 15 25 
34 25 42 8 26 18 19 
44 7 24 19 9 11 5 
58 23 18 34 27 15 21 
61 8 33 27 21 11 24 
68 38 33 34 27 17 21 
71 32 11 28 22 11 17 
83 52 38 40 14 18 24 
88 52 29 46 24 14 22 
89 21 23 31 22 18 13 
92 16 32 28 20 14 22 
95 16 20 26 23 15 21 
99 30 26 15 32 19 24 
106 45 47 37 31 13 20 
110 17 18 23 18 11 16 
111 8 26 17 6 13 19 
124 26 38 39 19 19 16 
125 24 45 37 26 15 24 
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Table.2.4   Raw scores for Choline 2 gm + Caffeine 100 mg group 
 
 
 
 
 
 
 
 
    Subject # 
      Story    
Memory 
      Design 
Memory 
     Verbal       
Learning 
 Picture     
Memory 
      Number 
Letter 
  Fingers 
Window 
1 40 30 33 28   
13 28 43 48 34 14 25 
20 29 47 27 34 19 15 
22 44 57 60 41 19 17 
26 37 48 39 29 19 25 
40 20 28 24 14 11 21 
41 32 35 23 26 17 20 
46 55 48 44 37 20 25 
48 42 49 39 39 15 21 
50 53 45 40 29 15 23 
51 46 42 36 32 15 22 
55 58 42 35 18 14 20 
62 40 37 32 29 17 22 
63 53 23 42 19 16 16 
65 29 30 33 27 13 20 
66 34 33 41 34 15 20 
76 22 37 26 36 22 18 
85 52 41 44 38 17 22 
93 34 25 24 30 21 19 
94 25 29 31 33 20 21 
101 48 35 45 28 12 21 
102 19 23 23 20 14 24 
103 40 34 34 31 11 20 
104 37 27 34 21 17 22 
105 42 32 34 26 13 21 
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Table.2.5                Raw scores for Placebo group  
 
 
 
 
 
 
       
    Subject # 
      Story    
Memory 
      Design 
Memory 
     Verbal       
Learning 
 Picture     
Memory 
      Number 
Letter 
  Fingers 
Window 
2 32 14 31 28   
4 33 44 18 22   
6 47 19 34 20   
8 51 47 46 25 11 21 
15 62 43 53 32 18 24 
16 33 41 40 41 15 18 
18 41 40 52 30 13 24 
24 54 47 39 26 17 20 
31 48 33 40 36 11 11 
35 40 36 36 26 17 25 
36 55 41 39 30 17 21 
39 52 40 33 29 13 25 
43 40 52 42 37 14 24 
47 29 34 30 27 15 17 
53 45 49 24 25 13 22 
54 13 30 22 20 18 23 
64 22 23 19 17 13 25 
75 35 42 13 36 13 24 
87 56 37 49 29 15 25 
91 40 43 31 38 19 25 
113 28 38 35 28 14 20 
114 28 38 34 28 16 16 
115 25 36 38 14 24 22 
116 19 28 34 15 13 23 
123 53 39 27 33 17 22 
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Table.3.1                Blood and Heart Rate for Choline 2 gm group  
 
 
 
 
    
 
 
Subject # S.B.P.0 D.B.P.0 H.R.0 S.B.P.30       D.B.P.30 H.R.30 
1 122 80 64 125 85 60 
10 122 85 70 120 80 72 
17 125 90 65 115 82 56 
21 120 80 74 120 80 72 
33 112 62 81 121 80 78 
38 120 83 61 120 83 57 
42 122 89 67 122 83 68 
45 124 81 74 120 76 66 
49 130 89 74 129 86 76 
52 129 89 78 136 88 77 
72 111 70 89 123 75 90 
73 121 85 76 127 86 76 
74 127 80 92 125 76 92 
78 120 80 72 120 81 74 
79 105 70 76 102 68 79 
80 120 80 65 121 82 82 
81 123 80       103 121 80 84 
86 120 80 74 121 83 89 
96 111 66 86 103 62 80 
100 134 95 96 157 93 89 
112 133 86 99 133 88 91 
117 120 80 77 120 80 77 
118 120 80 77 120 80 77 
121 130 75 85 139 75 95 
122 133 78 86 129 75 82 
S.B.P.0   = Systolic Blood Pressure at 0 mins  
S.B.P.30 = Systolic Blood Pressure at 30 mins  
D.B.P.0   = Diastolic Blood Pressure at 0 mins  
D.B.P.30 = Diastolic Blood Pressure at 30 mins  
H.R.0      = Heart Rate at 0 mins  
H.R.30    = Hear Rate at 30 mins  
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Table.3.2            Blood and Heart Rate for Choline 2 gm + Caffeine 25 mg group  
 
 
 
 
 
 
Subject # S.B.P.0 D.B.P.0 H.R.0 S.B.P.30     D.B.P.30 H.R.30 
3 132 90 66 114 80 68 
9 114 80 71 121 81 81 
14 127 81 67 127 81 68 
23 121 67 62 114 68 65 
25 126 73 71 115 62 63 
30 121 80 71 123 79 71 
37 130 82 85 124 81 88 
56 124 79 78 120 80 79 
57 105 65 74 110 70 71 
59 120 83 78 118 77 69 
60 121 78 78 116 73 63 
67 110 81 81 108 81 81 
69 127 83       100 127 80       100 
70 135 90       100 141 82       100 
77 121 80 72 120 80 72 
82 119 75 62 115 73 58 
84 121 80        71 121 80 71 
90 127 79 79 133 76 78 
97 133 87 91 140 90 91 
98 126 76 75 126 76 76 
107 151 82 90 151 82 90 
108 111 60 83 115 73 86 
109 122 73 87 128 87 79 
119 140 83 85 140 83 85 
120 114 74 72 114 74 74 
S.B.P.0   = Systolic Blood Pressure at 0 mins  
S.B.P.30 = Systolic Blood Pressure at 30 mins  
D.B.P.0   = Diastolic Blood Pressure at 0 mins  
D.B.P.30 = Diastolic Blood Pressure at 30 mins  
H.R.0      = Heart Rate at 0 mins  
H.R.30    = Hear Rate at 30 mins  
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    Table.3.3           Blood and Heart Rate for Choline 2 gm + Caffeine 50 mg group 
 
 
 
 
 
 
 
 
Subject # S.B.P.0 D.B.P.0 H.R.0 S.B.P.30      D.B.P.30 H.R.30 
5 128 95 92 127 90 84 
11 120 84 71 119 83 73 
12 119 66 80 123 68 73 
19 123 75 84 113 72 80 
27 128 86 87 118 76 77 
28 140 90 94 149 90 63 
29 123 84       107 111 79 90 
32 127 81 81 108 71 77 
34 132 82 63 132 82 63 
44 130 91 83 133 93 69 
58 116 70 82 114 79 79 
61 114 82 81 116 81 81 
68 124 86        65 128 83        66 
71 110 63        73 110 63        73 
83 122 79 82 121 82 69 
88 125 85 70 129 89 67 
89 93 56        67 127 61 67 
92 131 79 70 122 78 70 
95 131 73 84 130 72 81 
99 140 80 70 150 80 70 
106 120 79 81 118 80 86 
110 135 90 90 136 95 95 
111 136 81 81 135 80 80 
124 124 79 79 129 79 79 
125 125 51 71 115 65 78 
S.B.P.0   = Systolic Blood Pressure at 0 mins  
S.B.P.30 = Systolic Blood Pressure at 30 mins  
D.B.P.0   = Diastolic Blood Pressure at 0 mins  
D.B.P.30 = Diastolic Blood Pressure at 30 mins  
H.R.0      = Heart Rate at 0 mins  
H.R.30    = Hear Rate at 30 mins  
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    Table.3.4           Blood and Heart Rate for Choline 2 gm + Caffeine 100 mg group 
 
 
 
 
 
 
 
 
Subject # S.B.P.0 D.B.P.0 H.R.0 S.B.P.30 D.B.P.30 H.R.30 
1 115 64 80 115 80 66 
13 120 97 90 116 82 88 
20 128 60 81 123 81 61 
22 124 72 53 122 53 62 
26 113 88 72 117 73 89 
40 124 91 75 130 83 85 
41 130 70 80 129 80 70 
46 121 63 61 119 57 59 
48 126 70 77 122 75 59 
50 121 93 94 120 91 93 
51 129 79 82 126 81 79 
55 107 77 67 110 67 77 
62 135 80 80 133 79 84 
63 118 81 78 120 79 83 
65 121 69 65 120 70 70 
66 118 80 74 129 66 81 
76 140 102 95 147 86 93 
85 136 80 77 138 74 68 
93 112 63 70 104 63 60 
94 120 89 73 110 72 75 
101 116 65 68 116 68 65 
102 120 71 80 121 81 80 
103 120 70 80 121 81 70 
104 120 69 80 121 80 69 
105 120 72 80 120 80 72 
S.B.P.0   = Systolic Blood Pressure at 0 mins  
S.B.P.30 = Systolic Blood Pressure at 30 mins  
D.B.P.0   = Diastolic Blood Pressure at 0 mins  
D.B.P.30 = Diastolic Blood Pressure at 30 mins  
H.R.0      = Heart Rate at 0 mins  
H.R.30    = Hear Rate at 30 mins  
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Table.3.5          Blood and Heart Rate for Placebo group 
 
 
 
 
 
 
 
 
Subject # S.B.P.0 D.B.P.0 H.R.0 S.B.P.30 D.B.P.30 H.R.30 
2 122 80 78 125 85 72 
4 122 85 70 120 80 64 
6 125 90 64 115 82 72 
8 120 80 72 120 80 72 
15 112 62 91 121 80 90 
16 120 83 81 120 83 81 
18 122 89 63. 122 83 58 
24 124 81 73 120 76 71 
31 130 89 80 129 86 78 
35 129 89 79 136 88 74 
36 111 70 69 123 75 71 
39 121 85 87 127 86 79 
43 127 80 72 125 76 72 
47 120 80 82 120 81 82 
53 105 70 84 102 68 85 
54 120 80 72 121 82 72 
64 123 80 69 121 80 72 
75 120 80 72 121 83 72 
87 111 66 84 103 62 76 
91 134 95 72 157 93 69 
113 133 86 72 133 88 72 
114 120 80 72 120 80 72 
115 120 80 72 120 80 72 
116 130 75 72 139 75 72 
123 133 78 71 129 75 57 
S.B.P.0   = Systolic Blood Pressure at 0 mins  
S.B.P.30 = Systolic Blood Pressure at 30 mins  
D.B.P.0   = Diastolic Blood Pressure at 0 mins  
D.B.P.30 = Diastolic Blood Pressure at 30 mins  
H.R.0      = Heart Rate at 0 mins  
H.R.30    = Hear Rate at 30 mins  
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Table.4        Verbal Memory Index 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I II III IV V 
100 91 117 97 94 
102 94 67 97 72 
97 108 102 80 105 
94 120 88       123 120 
123 94 82 94 135 
88 97 105 72 97 
111 94 91 88 120 
85 102 88       111 111 
102 120 64       102 108 
74 108 62       105 94 
114 123 85       108 105 
62 80 67       108 100 
111 59 91 91 100 
102 108 82 117 82 
100 120 105 88 85 
100 97 111 97 72 
102 108 82 77 85 
94 91 74       108 72 
85 105 72 82 88 
126 102 69 82 117 
114 102 100       114 94 
77 108 74 74 85 
102 126 57 91 88 
94 123 88       100 82 
102 120 88 97 94 
I    = Choline 2 gm 
II  = Choline 2 gm + Caffeine 25 mg 
III = Choline 2 gm + Caffeine 50 mg  
IV = Choline 2 gm + Caffeine 100 mg  
V  = Placebo 
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Table.5                Visual Memory Index 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I II III IV V 
134 91 100 100 88 
85 124 85 109 97 
127 134 115 124 85 
106 124 118 144 121 
121 109 134 109 127 
112 112 141 76 130 
109 130 103 109 121 
82 109 115 121 115 
118 109 106 137 112 
100 127 73 112 94 
100 141 82 127 103 
70 100 88 103 100 
134 134 91 103 134 
137 127 70 85 100 
127 134 82 97 106 
82 145 85 109 97 
134 134 82 115 94 
121 144 94 115 112 
85 137 79 97 124 
144 127 91 97 103 
115 124 100 106 115 
67 115 82 84 103 
115 124 67 103 76 
97 106 100 94 82 
118 134 115 100 106 
I    = Choline 2 gm  
II  = Choline 2 gm + Caffeine 25 mg 
III = Choline 2 gm + Caffeine 50 mg  
IV = Choline 2 gm + Caffeine 100 mg  
V  = Placebo 
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Table.6                   Attention/Concentration Index 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I II III IV V 
112 88 62 115 103 
141 103 97 97 128 
112 103 88 103 100 
123 126 103 126 117 
  97 106 88 97 109 
128 117 97 115 70 
106 91 117 128 120 
128 112 109 109 109 
85 138 57 112 112 
91 123 109 117 112 
59 126 106 103 94 
82 138 109 115 103 
112 115 85 100 126 
109 143 120 100 120 
91 120 106 106 109 
106 112 94 117 117 
128 100 109 112 126 
131 131 106 120 109 
126 106 123 117 109 
106 134 100 100 94 
112 117 82 115 141 
126 145 94 94 112 
91 120 100 120  
117 126 115 103  
  115   
I    = Choline 2 gm  
II  = Choline 2 gm + Caffeine 25 mg 
III = Choline 2 gm + Caffeine 50 mg  
IV = Choline 2 gm + Caffeine 100 mg  
V  = Placebo 
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Table.7           Screening Memory Index 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I II III IV V 
92 110 110 98 89 
114 125 71 103 80 
100 127 110 101 94 
127 101 103 139 125 
100 105 109 101 137 
112 114 127 69 116 
80 107 96 98 125 
112 118 101 119 116 
84 121 80 123 112 
109 137 61 110 92 
60 87 80 121 105 
127 92 72 107 100 
123 121 89 96 119 
119 132 72 101 89 
114 125 92 91 94 
89 125 98 103 80 
121 119 79 94 87 
109 125 80 114 89 
92 118 71 87 107 
141 89 76 87 112 
118 116 110 112 105 
68 114 69 74 92 
110 130 55 96 79 
94 118 86 96 79 
112 132 94 98 100 
I    = Choline 2 gm 
II  = Choline 2 gm + Caffeine 25 mg  
III = Choline 2 gm + Caffeine 50 mg 
IV = Choline 2 gm + Caffeine 100 mg  
V  = Placebo 
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Table.8                 General Memory Index  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
I II III IV V 
99 102 63 109 120 
130 120 106 99 139 
105 121 97 13 112 
130 113 108 113 126 
98 106 114 75 116 
122 118 95 105 95 
87 110 109 127 104 
122 109 89 121 108 
81 133 55 113 105 
102 137 89 123 120 
55 102 81 106 89 
112 113 95 104 97 
122 122 73 101 109 
114 142 104 93 99 
87 127 101 105 95 
118 123 81 104 117 
120 114 89 116 117 
109 132 80 99 108 
140 116 91 98 91 
116 127 108 109 102 
80 118 69 86 87 
120 140 55 94 105 
91 122 89 106   
117 134 102    
I    = Choline 2 gm 
II  = Choline 2 gm + Caffeine 25 mg  
III = Choline 2 gm + Caffeine 50 mg 
IV = Choline 2 gm + Caffeine 100 mg  
V  = Placebo 
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Table. 9.1          MAP for Choline 2 gm group  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Subject #      MAP 0  MAP 30  
1 103 104 
10 92 93.3 
17 55 98 
21 72.3 70.3 
33 87.3 92.3 
38 91.3 92.3 
42 103.3 105.6 
45 102.3 103.3 
49 97.6 99.6 
52 93 93.3 
72 88 88 
73 102 105.3 
74 100 100.3 
78 94 94 
79 94.6 102 
80 87.6 97.3 
81 93 103 
86 105.6 100.6 
96 85.6 93.6 
100 95 93.3 
112 103 94 
117 94.6 99 
118 91.6 91.6 
121 87.3 100.6 
122 104.3 98.3 
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Table. 9.2                MAP for Choline 2 gm + Caffeine 25 mg group  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Subject #      MAP 0  MAP 30  
3 104 91.3 
9 91.3 94.3 
14 96.3 96.3 
23 85 83.3 
25 90.6 79.6 
30 93.6 93.6 
37 98 95.3 
56 94 93.3 
57 78.3 83.3 
59 95.3 90.6 
60 92.3 87.3 
67 90.6 90 
69 97.6 95.6 
70 105 101.6 
77 93.6 93.3 
82 89.6 87 
84 93.6 93.6 
90 95 95 
97 102.3 106.6 
98 92.6 92.6 
107 105 105 
108 77 87 
109 89.3 100.6 
119 102 102 
120 87.3 87.3 
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Table. 9.3              MAP for Choline 2 gm + Caffeine 50 mg group 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Subject #      MAP 0  MAP 30  
5 106 102.3 
11 96 95 
12 83.6 86.3 
19 91 85.6 
27 100 90 
28 106.6 109.6 
29 97 89.6 
32 96.3 83.3 
34 98.6 98.6 
44 104 106.3 
58 85.3 90.6 
61 92.6 92.6 
68 98.6 98 
71 78.6 78.6 
83 93.3 95 
88 98.3 102.3 
89 68.3 83 
92 96.3 92.6 
95 92.3 91.3 
99 100 103.3 
106 92.6       92.6 
110 105     108.6 
111 99.3 98.3 
124 129 95.6 
125 75.6 81.6 
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Table. 9.4                MAP for Choline 2 gm + Caffeine 100 mg group 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Subject #     MAP 0  MAP 30  
1 91.6 91.6 
13 100 93.3 
20 96.6 95 
22 76.6 76 
26 85.6 87.6 
40 91.3 98.6 
41 96.6 96.3 
46 81 77.6 
48 93.3 90.6 
50 103 100.6 
51 97.6 96 
55 80.3 81.3 
62 98.3 97 
63 91.3 92.6 
65 83.6 86.6 
66 88.6 87 
76 110 106.3 
85 96.6 95.3 
93 84 76.6 
94 88.6 84.6 
101 84        84 
102 93.3       94.3 
103 93.3 94.3 
104 93.3 93.6 
105 93.3 93.3 
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Table. 9.5               MAP for Placebo group  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Subject #      MAP 0 MAP 30 
2 94 98.3 
4 97.3 93.3 
6 101.6 93 
8 93.3 93.3 
15 78.6 93.6 
16 95.3 95.3 
18 100 96 
24 95.3 90.6 
31 102.6 100.3 
35 102.3 104 
36 83.6 91 
39 97 99.6 
43 95.6 92.3 
47 93.3 94 
53 81.6 79.3 
54 93.3 95 
64 94.3 93.6 
75 93.3 95.6 
87 81 75.6 
91 108 114.3 
113 101.6      103 
114 93.3       93.3 
115 93.3 93.3 
116 93.3 96.3 
123 96.3 93 
  99 
APPENDIX C 
Table.10      Summary of Age Distribution 
 
P value summary ns    
Do the variances 
differ signif. (P < 
0.05) 
 
No 
   
 
ANOVA Table SS MS   
Treatment (between 
columns) 
 
463.2 115.8   
 
Residual (within 
columns) 13610  
  
Total 14080     
 
Dunnett's Multiple 
Comparison Test 
Mean 
Diff. 
Significant? 
P < 0.05 Summary 
95% CI  
of diff 
Placebo vs Cho 3.600 No ns 
-3.855 to 
11.06 
Placebo vs 
Cho+25Caff 0.8400 No ns 
-6.615 to 
8.295 
Placebo vs 
Cho+50Caff 4.800 No ns 
-2.655 to 
12.26 
Placebo vs 
Cho+100Caff 0.3200 No ns 
-7.135 to 
7.775 
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Table.11    Verbal Memory Index 
 
 
 
 
 
 
 
 
 
 
 
P value summary Ns    
Do the variances 
differ signif. (P < 
0.05) 
No    
 
ANOVA Table SS df MS  
Treatment (between 
columns) 5101 4 1275 
 
Residual (within 
columns) 27980 120 233.2 
 
Total 32960 124   
 
Dunnett's Multiple 
Comparison Test 
Mean 
Diff. 
Significant? 
P < 0.05 Summary 
95% CI  
of diff 
Placebo vs Cho -1.800 No ns 
-12.49 to 
8.888 
Placebo vs 
Cho+25Caff -7.800 No ns 
-18.49 to 
2.888 
Placebo vs 
Cho+50Caff 11.88 Yes * 
1.192 to 
22.57 
Placebo vs 
Cho+100Caff 0.2000 No ns 
-10.49 to 
10.89 
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Table.12       Visual Memory Index 
 
P value summary ns    
Do the variances 
differ signif. (P < 
0.05) 
No    
 
ANOVA Table SS df MS  
Treatment (between 
columns) 10570 4 2642 
 
Residual (within 
columns) 35950 120 299.6 
 
Total 46520 124    
 
Dunnett's Multiple 
Comparison Test 
Mean 
Diff. 
Significant? 
P < 0.05 Summary 
95% CI  
of diff 
Placebo vs Cho -4.040 No ns 
-16.15 to 
8.075 
Placebo vs 
Cho+25Caff -17.52 Yes ** 
-29.63 to 
-5.405 
Placebo vs 
Cho+50Caff 11.12 No ns 
-0.9949 
to 23.23 
Placebo vs 
Cho+100Caff -0.6800 No ns 
-12.79 to 
11.43 
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Table.13   Attention/Concentration Index  
 
P value summary ns    
Do the variances 
differ signif. (P < 
0.05) 
No    
 
ANOVA Table SS df MS  
Treatment (between 
columns) 4573 4 1143 
 
Residual (within 
columns) 26560 113 235.1 
 
Total 31140 117    
 
Dunnett's Multiple 
Comparison Test 
Mean 
Diff. 
Significant? 
P < 0.05 Summary 
95% CI  
of diff 
Placebo vs Cho 1.784 No ns 
-9.426 to 
12.99 
Placebo vs 
Cho+25Caff -7.424 No ns 
-18.63 to 
3.786 
Placebo vs 
Cho+50Caff 11.91 Yes * 
0.6990 to 
23.12 
Placebo vs 
Cho+100Caff 0.8674 No ns 
-10.34 to 
12.08 
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Table.14      Screening Memory Index 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
P value summary ns    
Do the variances 
differ signif. (P < 
0.05) 
No    
 
ANOVA Table SS df MS  
Treatment (between 
columns) 10550 4 2638 
 
Residual (within 
columns) 32260 120 268.9 
 
Total 42820 124    
 
Dunnett's Multiple 
Comparison Test 
Mean 
Diff. 
Significant? 
P < 0.05? Summary 
95% CI 
of diff 
Placebo vs Cho -3.640 No ns 
-15.12 
to 7.837 
Placebo vs 
Cho+25Caff -15.16 Yes ** 
-26.64 
to -
3.683 
Placebo vs 
Cho+50Caff 13.60 Yes * 
2.123 to 
25.08 
Placebo vs 
Cho+100Caff -0.2800 No ns 
-11.76 
to 11.20 
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Table.15    General Memory Index 
 
P value summary ns    
Do the variances 
differ signif. (P < 
0.05) 
No    
 
ANOVA Table SS df MS  
Treatment (between 
columns) 11900 4 2975 
 
Residual (within 
columns) 25250 113 223.4 
 
Total 37150 117    
 
Dunnett's Multiple 
Comparison Test 
Mean 
Diff. 
Significant? 
P < 0.05? Summary 
95% CI 
of diff 
Placebo vs Cho 
-
0.07198 No ns 
-11.00 to 
10.86 
Placebo vs 
Cho+25Caff -13.86 Yes ** 
-24.79 to 
-2.935 
Placebo vs 
Cho+50Caff 17.51 Yes *** 
6.583 to 
28.44 
Placebo vs 
Cho+100Caff 1.511 No ns 
-9.417 to 
12.44 
 
 
 
 
 
 
 
 
 
